Risk Factors Update Summary
- New products may not be accepted or may generate lower revenues than anticipated.
- Revenues from pharmaceutical and biotechnology companies are a significant source of income.
- Inflation and interest rate increases could negatively impact future growth and demand for products.
- Outstanding borrowings decreased from $47 million to $37 million as of December 31, 2023.
- Failure to retain key personnel could result in reduced revenue and increased costs.
- Risks associated with cybersecurity incidents and evolving tactics adopted by threat actors.
- Foreign currency exchange rate fluctuations may negatively impact the company's performance.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1123494&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.